BET protein inhibition regulates macrophage chromatin accessibility and microbiota-dependent colitis
M. Hoffner O'Connor, A. Berglind, M. M. Kennedy, B. P. Keith, Z. J. Lynch, M. R. Schaner, E. C. Steinbach, J. Herzog, O. K. Trad, W. R. Jeck, J. C. Arthur, R. B. Sartor, T. Furey, S. Z. Sheikh
Abstract
IntroductionIn colitis, macrophage functionality is altered compared to homeostatic conditions. Loss of IL-10 signaling results in an inappropriate and chronic inflammatory response to bacterial stimulation. It remains unknown if inhibition of bromodomain and extra-terminal domain (BET) proteins alters usage of DNA regulatory elements responsible for driving inflammatory gene expression. We determined if the BET inhibitor, (+)-JQ1, could suppress inflammatory activation of macrophages in Il10-/- mice. MethodsWe performed ATAC-seq and RNA-seq on Il10-/- bone marrow-derived macrophages (BMDMs) cultured in the presence or absence of lipopolysaccharide (LPS) and with or without treatment with (+)-JQ1 and evaluated changes in chromatin accessibility and gene expression. Germ-free Il10-/- mice were treated with (+)-JQ1, colonized with fecal slurries and underwent histological and molecular evaluation 14-days post colonization. ResultsTreatment with (+)-JQ1 suppressed LPS-induced changes in chromatin at distal regulatory elements associated with inflammatory genes, particularly in regions that contain motifs for AP-1 and IRF transcription factors. This resulted in the attenuation of inflammatory gene expression. Treatment with (+)-JQ1 in vivo reduced severity of colitis as compared with vehicle-treated mice. ConclusionWe identified the mechanism of action associated with a new class of compounds that may mitigate aberrant macrophage responses to bacteria in colitis. FundingThis work was funded in part through Helmsley Charitable Trust (SHARE Project 2), NIDDK P01DK094779, NIDDK 1R01DK104828, NIDDK P30-DK034987, NIDDK 1R01DK124617, NIH Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship (1F31DK122704), NIH T32 Genetics NIGMS Training Grant (T32-GM007092-43), NIH T32 Translational Medicine Training Grant (T32-GM122741), NIH T32 Gastroenterology Research Training Grant (T32-DK007737), and Crohns and Colitis Foundation Student Research Fellowship Award, and Gnotobiotic Animal Facility.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IL-10 inhibits STAT1-dependent macrophage accumulation during microbiota-induced colitis
I. Patik, N. S. Redhu, … B. H. Horwitz·Mucosal ImmunologyPeer-reviewed·Jun 1, 2023
- Ameliorative effect of a quinazoline-based bromodomain inhibitor, CN210, on experimentally-induced Crohn's disease-like murine ileitis via inhibition of inflammatory cytokine expression
T. Noguchi, K. Hidaka, … S. Kato·bioRxiv·Jan 24, 2020
- Pharmacological inhibition of GPR4 remediates intestinal inflammation in a mouse colitis model
E. J. Sanderlin, M. Marie, … L. V. Yang·bioRxiv·Jan 29, 2019
- Colitis-primed circulating T cells drive small intestinal barrier function through Nod2, microbiota and myosin light chain kinase-dependent mechanisms
Arthur Mauduit, Talal Nabhani, … Ziad Al Nabhani·bioRxiv·Jul 10, 2025
- Adoptive transfer of CTLA4-Ig-modulated dendritic cells improves TNBS-induced colitis
L. N. Paiatto, F. G. D. Silva, … P. U. Simioni·bioRxiv·Jun 12, 2019
- DNAM-1 immunoreceptor integrates innate and adaptive immune programs to drive intestinal inflammation
Natsuki Ide, kazuki Sato, … Akira Shibuya·bioRxiv·Apr 1, 2026